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IMMUNITY AGAINST FUNGAL BETA 1,3 GLUCAN CARBOHYDRATE 
IN THE GASTROINTESTINAL TRACT 
MARIANELA FELIU 
ABSTRACT 
 Inflammatory Bowel Disease (IBD) is a debilitating, life- long disease that affects 
about 1.4 millions Americans. Little is known about the pathogenesis of IBD and an 
effective cure still remains to be discovered.  While there are numerous T cell targeting 
therapies for IBD, more research is still needed.  Bispecific T Cell Engagers, BiTES, is a 
modified protein capable of engaging two antigens simultaneously; it is capable of 
activating T cells by circumventing the MHC protein molecule.  This provides an 
alternative to the current molecular therapies for IBD.  In addition to monoclonal therapy 
research, there has been a plethora of research on immunomodulatory molecules, such as 
β- glucan.  The benefit of β-glucan has been shown with supplements and food sources 
alike in animal models.  In this study, we used BiTES, CMPD-1, with an anti-CD3/ 
Dectin-1 epitopes capable of engaging T Cells and β-glucan in beads and fungi cell wall.  
CMPD-1 is capable of engaging Splenic and Lamina Propia T Cells from a C57BL/6 
mice.  Likewise, CMPD-1 engaged T cells to hyphae of C. albicans and A. fumigatus, 
which have a higher concentration of β-glucan than in the candida form.  The data show a 
delayed in hyphae growth in yeast with CMPD-1 and a decrease in yeast growth for the 
first four hours when compared to non- BiTES molecules.   
 Additionally, qualitative analysis of CMPD-1 shows a decrease A. fumigatus 
growth after a 72-hour incubation period.  Splenic T cells from mice lacking Dectin-1 
  vi 
and Wild-type (WT) mouse strains where incubated with BiTES compound and yeast for 
23 hours followed by a PrestoBlue killing assay to assess yeast cell viability.  The 
PrestoBlue assay showed that CMPD-1 killed more A. fumigatus in both T cell subsets; 
although, the difference lacked statistical significance.  The applications of this molecule 
as a therapeutic agent for IBD are promising, although, still in its infancy.  An alternative 
use for this molecule is to train the immune system with the BiTES molecule in 
conjunction with β-glucan supplements to build immunity against opportunistic 
pathogens such as A. fumigatus and C. albicans that often cause havoc in IBD patients as 
a result of the changes in microbiota, and compromised integrity of the GI tract.    
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INTRODUCTION 
 
The microbiome consists of a diversity of microbes that confers a symbiotic 
relationship with humans.  Our microbiome plays an important role in metabolism, 
obesity and immunity. The Human Microbiome Project by the NIH, European project, 
and MetaHIT are large-scale projects focusing in understanding the biology of the human 
microbiota and its importance in health and diseases (Cho, et al. 2012 & Shreiner, et al. 
2015).  The specificity of the bacterial phyla that makes up the microbiota in humans is 
acquired by vertical transmission from the mother to the child during natural childbirth 
(Dominguez-Bello, et al. 2010).  Diet, environmental factors, and epigenetics can have an 
effect on the type of phyla of the microbiota the mother will pass to the offspring 
(Shreiner, et al. 2015).  The colonization of the microbiota in the infant’s gut is promoted 
by vaginal birth, breastfeeding, and the offspring’s epigenetics.  Studies have shown that 
Cesarean section birth, bottle-feeding, using antibiotics early in life, and genetics can 
skew the type of microbiota population in a person (Shreiner, et al. 2015).  Consequently, 
dysbiosis, microbiota imbalance, can lead to or be a harbinger of diseases such as 
colorectal carcinoma, cardiovascular disease, obesity, and Inflammatory Bowel Disease 
(IBD).  For example, too much Enterobacteriaceae bacteria in the gut has been linked to 
Inflammatory Bowel Disease (IBD) (Shreiner, et al. 2015).   
Furthermore, disruption of the microbiota has been associated with inflammation of 
the GI tract (Elinav, et al. 2011), and metabolic diseases (Vijay-Kumar, et al. 2010). 
Recent studies have shown that a small percentage of intestinal microorganisms are not 
bacteria (Qin, J. et al. 2010), but fungi (Scupham, et al. 2006), however, their role in 
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commensal immunity, if any, is poorly understood (Iliev et al., 2012).  Our bodies 
recognize fungal particle via Dectin-1 protein encoded by the CLEC7A gene in humans.  
Dectin-1 is a C-type lectin receptor capable of recognizing the β-1,3 glucan linkages 
found in the cell wall of most fungi (Iliev et al., 2012).  A deficiency in Dectin-1 receptor 
or its signaling pathway increases susceptibility to fungal infections (Iliev et al., 2012).     
Polymorphisms in genes responsible for important signaling pathways in both the 
adaptive, and innate immune systems have been associated to IBD (Shapiro et al., 2015).  
Furthermore, certain polymorphisms are known to affect epithelial cell function, which in 
turn creates a permeable lining to the alimentary canal; also known as, a leaky gut 
(Funderburg, et al. 2013).  However, a leaky gut alone is not sufficient to cause IBD.  It is 
the change in the intestinal microbiota in addition to a compromised GI lining that has 
been associated with IBD.  Interestingly, whether the change is the consequence of IBD 
or if it is the inflammatory response resulting from the change in the microbiome that 
causes IBD has yet to be established (Nagalingam, et al. 2012).  IBD is a debilitating 
disease consisting of persistent inflammation in either a specific area or the entire GI 
tract.  The most common types of IBD are as follows:  Crohn’s disease (CD) and 
Ulcerative Colitis (UC).  CD is characterized as inflammation in the lining anywhere 
within the GI tract.  UC is characterized by persistent inflammation and ulcers limited to 
the colon.  
Although the pathogenesis of IBD still remains a mystery, the disease is a result of 
an aberrant immune response to the microbiome in genetically prone individuals 
(Geremania, et al. 2014).  Thus, these data show that both the innate and the adaptive 
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immune system play a significant role in the development of IBD.  Briefly, the innate 
immune response provides the first line of defense.  This response is non-specific; it 
initiates a rapid and ferocious inflammatory response against microbes.  As a downstream 
consequence to the innate immune response, T cells get activated mounting a specific 
immunological response (Geremania, et al. 2014).  Consequently, T cells in the lamina 
propia become resistant to apoptosis, thus propagating the immune response 
(Monteleone, et al. 2010).  
 Hence, T cells play an important role in the pathology of IBD.  T cells are 
recruited to the lamina propia from the blood stream by increased chemokine production 
from epithelial cells in the GI tract (Monteleone, et al. 2010).  Once in the lamina propia, 
T cells undergo proliferation and resist apoptosis, thus, exacerbating the inflammatory 
response seen in IBD patients (Monteleone, et al. 2010).  As a result, there has been an 
increase in T cell directed therapies to treat IBD.  For example, some of these therapies 
target the ability of T cells to travel to the mucosa of the GI tract, T cell proliferation 
inhibitors, and apoptosis inducers (Monteleone, et al. 2010).   However, more recently, a 
Bispecific T Cell Engagers ‘BiTES’ have been manufactured as an alternative to the 
current T cell directed therapies in the market.  A BiTE® is a manufactured protein with 
two different monoclonal antibodies on opposite ends allowing it to bind to two different 
antigens.   
It has the ability to engage specific receptors forcing cell targets to interact and 
create a connection otherwise not achievable.  The BiTE® currently undergoing clinical 
trials or that have already been approved by the FDA have been generated for cancer 
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therapy (Kontermann, et al. 2015).  The BiTES used in this study is capable of targeting 
the β-1,3 glucan linkages found in the cell wall of fungal pathogens, and the first one 
created for fungal therapy.  Fungal infections are most often caused by opportunistic 
pathogens, like Aspergillus furmigatus and Candida albicans.   These pathogens cause 
infections in immunocompromised patients, as seen with HIV, organ transplant and 
cancer patients.  Unfortunately, there is a high mortality rate resulting from resistance to 
antifungal therapy drugs.   
The BiTES of interest in this study is referred to as CMPD-1; it has an anti-CD3 
and a mouse Dectin-1 (homo-dimer) paratopes held together by an Fc region.   CMPD-1 
simultaneously binds to the CD3 T cell co-receptor and a variety of β-1,3 linked glucan 
found in the cell wall of fungal pathogens, oatmeal, and edible mushrooms.  Two 
alternative molecules, CMPD-2, has one epitope for the mouse Dectin-1-Fc conjugate 
(homo-dimer).  A negative control molecule, consisting of the Fc region and no antigen-
binding domain was used as well.  In this study, I demonstrated that CMPD-1 is able to 
engage T cells to β glucan particles, and decrease Aspergillus furmigatus and Candida 
albicans growth. β glucan, is a molecule mostly known for its cholesterol lowering 
abilities, additionally it has immunomodulating properties.  Chan, et al. 2009, showed in 
an animal study that oral administration of β glucan activates immune cells eliciting both 
an innate and adaptive immune response.   
The ability to elicit and immune response via food supplementation can be used 
as a way to train the immune system to respond faster to opportunistic fungal infections, 
especially in immunocompromised patients regardless of their genetic susceptibility to 
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IBD.  The possibility of using β glucan and CMPD-1 as a way to help 
immunocompromised patients fight opportunistic fungal infections faster or avoid such 
infectious might be possible.  However, before we can make move to clinical trials, much 
more basic research needs to be done to establish the efficacy of orally administered β 
glucan as an immunomodulator in humans.  In addition, more basic studies needs to be 
done to determine BiTES efficacy in engaging T cells to kill fungal infections, cell 
toxicity, and eventually dosage.
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MATERIALS AND METHODS 
Mice 
CLB6/9 mice were originally bought from Jackson laboratory (Bar Harbor, ME) 
and D1KO were obtained from Brahm Segal (Roswell Medical Center) and bred 
thereafter at MGH. Mice used in this study were housed and cared for in the MGH Thier 
SPF barrier facility according to IACUC guidelines.   
 Splenic T Cell Isolation 
  Mice were euthanized following IACUC’s euthanasia protocol at MGH.  An 
incision was made in the skin, to isolate spleen. The spleen was cut in two, and gently 
ground using the frosted white sides of microscope slides.  The tissue was ground until 
little red tissue was left.  Microscope slides were rinsed with ice-cold 1X PBS on a petri 
dish, and pipette into a 50 mL Falcon tube.  Additional 1X PBS was used to rinse off 
remaining cells in Petri dish.  Splenocytes were spun at 1200 rpm for 10 minutes.  
Supernatant was aspirated and pellet was resuspended in 5 mL of ACK lysis buffer and 
incubated at room temperature for 5 minutes.  Lysis was stopped by adding 45 mL of 
complete RPMI, and centrifuged at 1200 rpm for 10 minutes.  Supernatant was aspirated 
and pellet was resuspended in 10 mL complete RPMI.  Cells were strained using a 40um 
nylon cell strainer (BD Falcon 352340).  Cells were counted using a hemocytometer. T 
cells were freshly harvested for each experiment.   
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Lamina Propia T Cell Isolation  
Small intestines of B6 mice were harvested.   All Peyer’s patches, fat, and 
mesenterium were removed.  Intestines were flushed with a plastic transfer pipette to 
remove fecal content; they were cut open longitudinally and with a razor blade were 
chopped into small pieces.  The pieces were placed into a 70 micron cell strainer in a 
small culture dish with 12 mL 1X HBSS/ 5% FBS (used Ca2+ and Mg2+ free HBSS).  The 
tissue was washed twice with 1X HBSS/ 5% FBS at room temperature stirring for 5 
minutes.  To dissociate mucus, epithelial cells, and intraepithelial lymphocytes, tissues 
were placed in pre-warmed (37°C) epithelia strip buffer (1X HBSS + 5mM EDTA + 
1mM DTT + 5% FBS + 15mM HEPES) stirring for 30 minutes at 37°C.  The tissue were 
washed twice with 1X HBSS/ 5% FBS at room temperature stirring for 5 minutes.  This 
was followed by 15 minute incubation at 37°C in 1X HBSS/ 1% FBS/ 15mM EDTA 
while stirring followed by two more washes as mentioned above. Tissues were incubated 
for 10 minutes at room temperature in 12 mL of EDTA free wash media (1X HBSS/ 1% 
FBS/ 15 mM HEPES).  After washing for 10 minutes in 1X HBSS/ 5% FBS, tissues were 
incubated for 45 minutes at 37°C in enzyme solution (5mg Liberase TL (Roche, Cat. # 
05401020001) + 0.1 mg/ml DNAse in EDTA- Free wash media).  The supernatant was 
collected and filtered through a 70 micron cell strainer then washed with 20 mL of wash 
media (1X HBSS/ 1% FBS/ 1mM EDTA).  This was spun down at 1760 rpm for 6 
minutes.  The pellet was resuspended in 4.5 mL of 44% Percoll, and transferred to a 15 
mL conical tube.  A second phase consisting of 2.3 mL of 67% Percoll was slowly 
underlaid leaving two distinct phases clearly visible to the naked eye.  
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 The 40%/67% Percoll gradient with cell mixture was centrifuged at 600 x g for 20 
minutes at 20°C with smooth acceleration and no brake.  The lymphoid fractions were 
found as part of a turbid ring at the 44%-67% interphase.  The lymphoid fraction was 
collected, washed and spun down at 1200 rpm for 5 minutes followed by magnetic 
labeling and T cell isolation.         
Manual Magnetic labeling and separation of T cells 
 Using the Pan T Cell Isolation Kit II, mouse (MACS®, Miltenyi Biotec Cat. # 
130-095-130) Lymphocytes were suspended in 40uL of MACS® buffer. Biotin- antibody 
cocktail, 10µL was added and incubated on ice for 5 minutes.  30uL of MACS® buffer 
was added followed by 20µL of anti-biotin microbeads and incubated on ice for 10 
minutes. To negative select T cells of interest, an LS column was placed in the magnetic 
field of a suitable MACS® separator.  Column was prepared by rinsing with 3 mL of 
MACS® buffer.  The cell suspension was added to the column; the flow through, 
representing the enriched T cells, was collected, and centrifuged at 1200 rpm for 5 
minutes.  The pellet was resuspended with Complete RPMI.  Cells were counted using a 
hemocytometer followed by additional experiments.   
Fungal Strains and growth 
 The wild-type Candida albicans strain SC5314 and Aspergillus fumigatus wild-
type strain 293 were gifts from Eleftherios Mylonakis (Massachusetts General Hospital, 
Boston, MA).  A. fumigatus was grown on Sabouraud dextrose agar plates supplemented 
with 100 µg/ml ampicillin at 30°C for 3 to 5 days and then harvested by scraping and 
washing three times in phosphate-buffered saline (PBS).   
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C. albicans yeast was grown overnight at 30°C  in yeast extract-peptone-dextrose (YPD) 
medium.  Yeast cells were then washed three times in PBS.  Yeast was counted using a 
hemocytometer and adjusted to the desired organism density prior to use.  Fungi were 
grown fresh for each experiment (Kasperkovitz, et al. 2011).   
PrestoBlue® Cell Viability Assay  
 PrestoBlue® cell viability reagent is a ready to use resazurin-based solution 
permeable to non-mammalian cells and was used as an indicator of yeast cell viability.  
This resazurin-based reagent was added directly to yeast cells in a 96 well plate.   
Resazurin (blue) is reduced to the resofurin (pink) product by live yeast cells.  T cells 
were freshly harvested and 1 x 105 T cells/ well, exposed to 5 x 103 yeast cells/well and 
CMPD-1, CMPD-2, and control compounds at a concentration of 10 µg/ml were plated in 
triplicates in a 96 well plate (Costar, Cambridge, MA) and co-incubated overnight at 
37°C.  To facilitate lysing of the aforementioned T cells, 4X NP40 solution was added to 
every well at the same time.  PrestoBlue® (Thermo Fisher Cat. # A13261) reagent at a 
concentration of 1X was added directly to the 96 well plate.  Fluorescence was detected 
using a SpectraMax i3x plate reader at excitation/ emission wavelengths of 560/ 590 nm 
respectively. The plate was read overnight at every hour at a temperature of 30°C.  Data 
was expressed as mean fluorescence.  Fluorescence values are inversely proportional to 
fungi killing.  Standard Deviation (SD) was calculated using Graphpad.  Errors were 
calculated based on the errors associated with each measurement.  This experiment was 
repeated six times in triplicates.   
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Confocal microscopy 
  Spinning disk confocal microscopy was performed on cells plated in complete 
medium in a chambered cover glass (Lab-Tek/Nunc, ThermoScientific, Rochester, NY) 
in a temperature-regulated environmental chamber. Fluorescence fungal surface labeling 
and live-cell imaging were performed on a Nikon Ti-E inverted microscope equipped 
with a CSU-X1 confocal head (Yokogawa). A coherent, 4-W, continuous-wave laser was 
used as an excitation light source to produce excitation at a wavelength of Widefield RFP 
through CSU. To acquire quality fluorescence images, magnification of 40 X was used 
(Nikon). A halogen light source and air condenser (0.52 NA) were used for bright-field 
illumination, and a polarizer (MEN51941; Nikon) and Wollaston prisms (MBH76190; 
Nikon) were used to acquire differential imaging contrast (DIC) images. Images were 
acquired using an electron-multiplying charge-coupled device (EM-CCD) camera 
(C9100-13; Hamamatsu) and MetaMorph software (Molecular Devices, Downingtown, 
PA) (Kasperkovitz, et al. 2011).   
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RESULTS 
The cartoon depiction of the Bispecific T-cell Engagers ‘BiTES’ used in this study.               
The BiTES, CMPD-1, molecule used in this study has two different monoclonal 
antibodies on opposite ends allowing it to bind to two different antigens. The BiTES, 
CMPD-1, has an anti-CD3 and a mouse Dectin-1 (homo-dimer) paratopes held together 
by an Fc region (fig. 1B).  CMPD-1 simultaneously binds to the CD3 T cell co-receptor 
and a variety of β-1,3 linked glucan found in the cell wall of fungi particles (fig. 1A).  An 
alternative molecule, CMPD-2, has one monoclonal antibody, consisting of mouse 
Dectin-1-Fc conjugate (homo-dimer) (fig. 1C).  Lastly, a control molecule, consisting of 
only an Fc region and no antigen-binding domain (fig. 1D) was used as a negative 
control.  
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Splenic T cells with ‘BiTES’, CMPD-1, compound engages β-1,3 glucan beads.   
Prior to this, our lab had never worked with these compounds.  I sought out to 
verify that CMPD-1 is capable of engaging β linked glucan particles found in the cell 
wall of fungi particles, I ran a series of experiment using β-1,3 glucan beads. 
 
Figure 1:  Cartoon depiction of the Bispecific T-cell Engagers “BiTES” used 
in this study. (A) BiTES, CMPD-1, linking a T Cell to a fungal particle. (B) 
BiTES, CMPD-1 structure. It contains a Fragment Antigen-Binding (fab) 
fragment on opposite ends of the molecule. On one end it has an anti- CD3, and a 
Dectin-1 antigen-binding fragment. (C) CMPD-2 structure. It contains a single 
Fragment Antigen-Binding (fab) fragment to Dectin-1. (D) shows the structure of 
the control compound. It contains an FC region with no antigen-binding domain.  
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 Figure 2: Splenic T cells with ‘BiTES’, CMPD-1, compound engages β-1,3 glucan beads.  
Panel A- Figures A-D & E-H, shows T cells and BiTES, CMPD-1, engaged to three β-glucan beads 
(see arrows) for a total of 70 minutes and 80 minutes respectively. Panel B- Figures A-D & A’-D’ 
shows T cells and control compound, loosely engaging with β-glucan beads and dissociating minutes 
later, see arrows. Panel C- Figures A-D & A’-D’ shows T cells and CMPD-2, engaging with β-glucan 
beads and dissociating a minute later (see arrows).  The experiment shown is one of three independent 
experiments.   
 
A 
 
B 
C 
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I observed that splenic T cells with BiTES, CMPD-1, are capable of engaging β-
1,3 glucan beads with high affinity.  In images A-D (fig. 2, panel A), T cells are shown 
engaged to the same β glucan beads without disengaging for 70 minutes.  Likewise, in 
images E-H (fig. 2, panel A) also shows a set of T cells engaged to β glucan beads 
without dissociating for 80 minutes.  In figure 2, panel B, images A-D shows several T 
cells incubated with control compound showing momentary association with the β glucan 
beads.  Images A’-D’ in panel B, figure 2 shows the T cells dissociating from the β 
glucan beads.  In addition, T cells incubated with CMPD-2, also show momentary 
association with glucan beads as seen in images A-D, in figure 2, panel C.  The 
corresponding figures A’-D’ show the dissociation of T cells to the beads as highlighted 
by the corresponding arrows.  The momentary binding seen in panels B and C in figure 2 
is a result of Brownian motion throughout the imaging process and not true binding as 
seen in Panel A, fig. 2.  I concluded that BiTES, CMPD-1 is capable of binding to β-1,3 
glucan. 
T cells isolated from the lamina propia of the small intestine with ‘BiTES’, CMPD-1 
compound engages β-1,3 glucan beads.    
To determine if there is a difference in behavior from splenic T cells and lamina 
propia T cells in the presence of the compound in the study, I isolated T cells from lamina 
propia of the small intestine.  The LP T cells were incubated overnight with the 
compound of interests and β glucan beads and imaged overnight.  The datum suggests 
that both splenic T cells and Lamina propia isolated T cells exhibit the same behavior in 
the presence of the compounds and the glucan beads.  
15 
 
 
  
 
      
 
 
 
B 
C 
Figure 3: T cells isolated from the lamina propia of the small intestine with ‘BiTES’, CMPD-1 
compound, engages β-1,3 glucan beads.  
Panel A- Figures A-C, shows T cells with BiTES, CMPD-1 compound engaged with β-glucan beads, 
see arrows, for twenty minutes without dissociating.  Panel B- Figures A-C, shows T cells with 
CMPD-2 briefly interacting with β-glucan beads for two minutes before dissociating, as highlighted 
by arrows in images.  Panel C- Figures A-C, shows T cells with the control compound briefly 
interacting with β-glucan beads for two minutes before dissociating as highlighted by arrows.  The 
experiment shown is one of three independent experiments.   
 
A 
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Figure 3, panel A, shows lamina propia T cells incubated with CMPD-1 and β glucan 
beads.  Images A-C shows a group of T cells engaged to β glucan beads for 20 minutes 
without dissociating.  In panel B, images A-C, shows T cells incubated with CMPD-2 
and β glucan beads. In general, panel B shows a slight longer momentary interaction than 
seen with splenic T cells (fig. 2, panel C). Panel C, shows T cells incubated with β glucan 
beads and the control compound; displaying a brief interaction between the glucan bead 
and the T cells similar as seen in splenic T cells (fig. 2, panel B).  I concluded that lamina 
propia T cells behave similar to splenic T cells, and thus, in the presence of BiTES, 
CMPD-1, is capable of engaging β-1,3 glucan. 
Splenic C57BL/J6 T cells with CMPD-1 do not bind to Mannan beads. 
 In order to validate that CMPD-1 and CMPD-2 had Dectin-1 epitopes that should 
only recognize and bind to β glucan linkages, I incubated splenic T cells with the 
compound of interest with mannan beads.  As expected, in panels A, B, and C of figure 4, 
shows T cells with control compound, CMPD-2, and CMPD-1 respectively.  Overall, 
figure 4 shows T cells with the respective compounds interacting with Mannan beads for 
a brief moment and quickly dissociating.  This confirms that CMPD-1 has a Dectin-1 
epitope that only recognize β glucan linkages.  Mannan beads have α- glucan linkages not 
recognized by the Dectin-1 epitope in CMPD-1.  Therefore, I conclude that T cells 
incubated with CMPD-1 do not bind glucan linkages found in mannan.  
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A 
B 
C 
 
Figure 4: Splenic T cells with CMPD-1 compounds do not bind Mannan beads.  
Panel A- Figures A-C, shows T cells with Control compound momentarily bind to Mannan beads. 
Figures A’-C’ show T cells disengaging Mannan beads a minute later, respectively, as highlighted 
by arrows. Panel B- figures A-C, shows T cells with CMPD-2 momentarily bind Mannan beads. A 
minute later, T cells disengage the Mannan beads as shown in figures A’-C’, respectively, see 
arrows above. Panel C- Figures A-F, shows two T cells (see black and white arrows) with BiTES 
compound, CMPD-1 interacting with two beads; loosely binding and coming off every minute for 
five minutes. In all panels, T cells do not bind Mannan beads longer than a minute. The experiment 
shown is one of three independent experiments.   
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Splenic T cells with ‘BiTES’ engages β-1,3 glucan in the cell wall of Candida  
albicans.   
 The next logical step in the development of this study was to see if the behavior 
exhibited in figure 2, panel A would hold true when incubated with the yeast, Candida 
albicans.  Figure 5A, panel A, images A-H, shows T cells incubated with the control 
compound and C. albicans briefly interact with the yeast in both its spore and its mycelial 
forms.  The brief interaction between the T cells and the spore takes place for the first 50 
minutes. Thereafter, this interaction occurs between the hyphae and T cells, repeatedly 
for approximately 4 hours.   Panel B, images A-H, shows T cells with CMPD-1 and C. 
albicans.  Image A, shows T cells briefly engaging β glucan cell wall of yeast.  
Thereafter, T cells interact mainly with the cell wall of β glucan in the mycelial form of 
C. albicans, as seen in images B-H of panel B.  Lastly, panel C, images A-H shows T 
cells with CMPD-2 and yeast.  T cells are shown briefly interacting with mainly the 
hyphae of C. albicans.  Based on figure 5A, I conclude that T cells with CMPD-1 do 
engage cell wall of C. albicans.  In figure 5B, quantification of hyphal growth during the 
first 4 hours is graphed.  The graph suggests that yeast incubated with CMPD-1 grows 
two to there times slower than the yeast incubated with CMPD-2 and control compound 
respectively. It also appears to be a delay in hyphal growth in yeast incubated with 
CMPD-1.   
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Figure 5A: Splenic T cells with ‘BiTES’ engages β-1,3 glucan in the cell wall of the yeast, 
Candida albicans.  Panel A: A-H shows T cells and control compound briefly binding to both the 
yeast and hyphal forms of C. albicans. The interaction lasts several minutes; see arrows, eventually 
dissociating. Panel B: A-H, see arrows, shows T cells with ‘BiTES’, CMPD-1, engaged to both the 
yeast and hyphal forms of C. albicans. T cells stay attached, and move along the hyphae without 
disengaging. This interaction goes on for 10 minutes in images A-D, and 40 minutes in images E-
H.  Panel C: A-H shows T Cells with CMPD-2, binding mainly to the hyphae form of C. albicans. 
This momentary interaction, see arrows, can be seen specifically in images E-H, giving the 
appearance of cells crawling and jumping off the hyphae. This experiment is one of three 
independent experiments.   
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Splenic T cells incubated with ‘BiTES’, CMPD-1 and Aspergillus fumigatus for 72 
hours qualitatively shows a decrease in hyphal growth.   
Since data in fig. 5A showed CMPD-1 could engage the β-1,3 glucan cell wall of 
C. albicans I wanted to see, if the same would hold true with A. fumigatus.   T cells were 
incubated and imaged with CMPD-1, CMPD-2, and control.  An observation made after 
72 hours from an overnight experiment showed that the yeast, Aspergillus fumigatus 
hyphal formation is decreased.  In figure 6A, Panel A, images A & B, shows T cells 
incubated with CMPD-1 and yeast.   
 
 
Figure 5B: Analysis of yeast C. albicans hyphal growth over time. (This graph 
is an analysis of images in figure 5A).  
Yeast incubated with splenic T cells, yeast, and compounds (CMPD-1, CMPD-2, 
and control), were imaged overnight.  Hyphal growth was measured over 4 hours 
for the respective compounds. Yeast incubated with ‘BiTES’, CMPD-1, and T 
cells showed a delayed hyphae growth and shorter hyphae. CMPD-1 had hyphae 
that were approximately two to three times shorter than hyphal growth seen in 
yeast incubated with T cells and CMPD-2, and control compound, respectively.  
Graph represents n=1. 
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Panel B, images A & B shows T cells incubated with CMPD-2 and lastly, panel C 
images A & B, show T cells incubated with the control compound.   These images show 
a qualitative difference between the visible hyphal growth in Aspergillus fumigatus in 
images seen in panels A, B, and C respectively.  Furthermore, in panels B and C, there 
are more hyphae and more T cells present than seen in Panel A.   In addition, a picture of 
the plate (fig. 6B) shows the visible layer of A. fumigatus mold growing on the top layer 
of wells incubated with T cells, compound, and yeast.  Looking at the plate (fig. 6B), (A) 
represents T cells alone. (B) Shows T cells, with CMPD-1, and yeast. (C) Has T cells 
with CMPD-2, and yeast and finally, (D) Has T cells with control compound and yeast.  
Counterclockwise, starting with A, there is a noticeably increase in mold growth in wells 
B, C, and D respectively.   In order to quantify the observations seen in figure 6A, and 
6B, I ran a PrestoBlue® killing assay. Figure 6C, shows splenic C57BL/J6 and D1KO T 
cells incubated with CMPD-1 and A. fumigatus shows decreased growth inversely related 
to the mean fluorescence. In both C57BL/J6 and D1KO T cells, there is less inhibition of 
yeast growth in the presence of CMPD-2, control compound, and cells with yeast only, 
respectively.  The difference in yeast growth is not statistically significant, however, 
there is a difference and further experiments should be performed.   
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Figure 6A: Splenic T cells incubated with ‘BiTES’, CMPD-1 and Aspergillus 
fumigatus for 72 hours qualitatively shows a decrease in hyphal growth.  
Panel A- Figures A & B, represent T cells incubated with ‘BiTES’, CMPD-1 and A. 
fumigatus shows an overall decreased in A. fumigatus hyphal growth.  Panel B - Figures A & 
B, shows T cells incubated with CMPD-2 and A. fumigatus. Panel C- Figures A & B, shows T 
cells incubated with the control compound and A. fumigatus.  Both panel B and C, show more 
hyphal growth and more T cells in comparison to Panel A. The experiment shown is one of 
three independent experiments.   
 
A 
B 
C 
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Figure 6B: Plate representation of Splenic T cells incubated with Aspergillus 
fumigatus for 72 hours.   
(A) Shows well with T cells alone with no compound and no A. fumigatus.  (B) 
Shows well with T cells and ‘BiTES’, CMPD-1 with A. furmigatus. (C) Shows 
well with T cells and CMPD-2 with A. fumigatus. (D) Shows well with T cells 
and control compound with A. fumigatus. This plate qualitative shows an increase 
in yeast growth in wells B, C, and D respectively.  
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Figure 6C: ‘BiTES’, CMPD-1, compound decreases A. fumigatus growth in 
both splenic B6 and D1KO T cells.    
The mean fluorescence is inversely proportional to yeast killing. ‘BiTES’, CMPD-1, 
decreases A. fumigatus growth in both splenic B6 and D1KO T cells more than seen 
with CMPD-2, control or T cells and yeast only.  Error bars are SEM of n=3. The 
results shown are from two independent experiments run in technical triplicates.   
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DISCUSSION 
 
 It was confirmed that BiTES, CMPD-1 does bind to β glucan beads and the cell 
wall of fungi of Aspergillus fumigatus, and Candida albicans. As it was established in 
figure 2 (panel A), data shows that CMPD-1 is capable of engaging T cells to β glucan 
beads for more than 60 minutes without disengaging.  This long interaction with glucan 
particles suggests that T cells would get activated since it binds to the CD3 component of 
the T Cell Receptor (TCR).  CMPD-1 along with β glucan supplements could serve as a 
way to train the immune system to become more efficient at fighting off opportunistic 
fungal infections.  Although the possibility for a synergistic relationship between  
CMPD-1 and β glucan particles sounds promising, independent and carefully designed 
human studies establishing the efficacy of orally administered β glucan must first be 
accomplished.  Thereafter, CMPD-1 would need to be validated to determine efficacy 
fighting opportunistic fungal infections.   
 In order to ensure that there were no differences in behavior from splenic T cells 
and LP T cells, I successfully isolated lymphocytes from the Lamina propia.  The data 
shows that both subsets of cells behave similarly as seen when CMPD-1 engages β 
glucan beads for more than 20 minutes.  This suggests that T cells in the gut would be 
able to engage to an efficient dose of oral supplements of β glucan with CMPD-1 with 
the goal to train the immune system and fight fungal infections more effectively.  A 
limitation to this study is that the Pan T Cell Isolation Kit II, mouse used was not 
optimized for T cell isolation from the lamina propia.   
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Therefore, the experiment was repeated with lymphocyte fraction of the lamina propia 
and it showed cells engaging with CMPD-1 for the same time as seen in figure 3.  LP 
lymphocytes did not engage to glucan beads in the presence of CMPD-2 and the control 
compound as long as it did with CMPD-1.  
 In addition to testing T cells from different organs. I decided to test the compound 
against mannan beads.  Since mannan is composed of α glucan linkages, I hypothesized 
that the splenic T cells incubated with the compound in this study should not bind.  In 
fact, that is exactly what is seen in figure 4.  This validates that CMPD-1 specifically 
engages β glucan linkages and will not engage other carbohydrates that are present in the 
cell wall of fungal pathogens.   
 The next step was to incubate splenic T cells with Candida albicans with the 
CMPDs to see if there would be a difference in T cell engaging behavior to the fungal 
particle.  Data show that CMPD-1 with T cells engages C. albicans in both of its form, 
yeast and mycelial forms, however, it preferentially binds to the mycelial hyphal growths. 
This is an important distinction to be aware of because the concentration of β glucan in 
the yeast spore and mycelial form of C. albicans, explicitly; the mycelial form has a 
higher concentration of β glucan.  It is important to keep in mind that fungi carbohydrates 
are arranged in pockets of mannan, β glucan, Chitin and other saccharides.  Therefore, as 
the morphology of the fungus form changes, therefore, the carbohydrate composition will 
also change, thus exhibiting a behavioral difference among T cells, yeast, and BiTES 
CMPD-1. 
Thus, as predicted, we see that T Cells with CMPD-1 engages with the mycelial 
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form at different areas, giving the appearance that cells are crawling along the hyphae 
without dissociating (fig. 5A, panel B, images E-H).  Glucan beads, CMPD-1 and T Cells 
has a more robust interaction because the bead has evenly distributed β glucan linkages, 
not pockets of β glucan as in fungal cell wall.  Conversely, with CMPD-2, the interaction 
of yeast and cells is momentary as seen in figure 5A, panel C, images E-H, giving the 
appearance that T cells are jumping off the hyphae.   
Curious to see if yeast growth was inhibited as a result of the interaction between 
T cells incubated with CMPD-1, I decided to quantify yeast growth during the first four 
hours. With CMPD-1 delayed hyphal growth for approximately 30 minutes, and overall 
hyphal growth was two to three times less than seen other compounds.   The limitation to 
this analysis came from the images itself.  It was difficult to capture the behavior of a 
single yeast past four hours because the yeast would grow out of the field of view or they 
hyphae would contort itself in and our of the field of view, or the hyphae would grow out 
of the field of view.  Therefore, to limit bias, the analysis was limited to the first four 
hours.  
 Lastly images taken after 72 hours of incubation (fig. 6), shows a qualitative 
difference in Aspergillus fumigatus’ hyphal growth.  Images in Panel A show overall less 
hyphal growth, and less T cells when compared to the images in panels B & C.  In Panels 
B & C, there is overall more hyphal growth, and more cells lingering around the yeast.  
Based on the images in panel B & C, yeast growth seems to be about the same suggesting 
that there wasn’t much of a difference between CMPD-2 and he negative control.   
The reduction of T cells in panel A, but not in Panels B & C is interesting.  This could 
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mean that activated T cells could have undergone apoptosis as a result of the TCR-CD3 
association with yeast via CMPD-1 since studies have shown that activation of T cells by 
engaging TCR-CD3 complex induces apoptosis to prevent hyperstimulation (Carpenter, 
et al. 2000).  Since part of the pathogenesis of IBD is accumulation of T cells that resist 
apoptosis, having a molecule that would engage T cells to decrease yeast growth, and 
induce T cell apoptosis would help fight fungal infectious in IBD patients as well as 
decrease inflammatory response.  The plate shown in figure 6B, shows A. fumigatus 
visibly growing.  An increase in yeast could be seen counterclockwise starting with well 
B to C to D corresponding to CMPD-1, CMD-2, and control respectively.   
Intrigued by the difference of yeast growth observed in these wells, I decided to do a 
PrestoBlue® killing assay on splenic T cells from B6 and D1KO mice.   D1KO mice were 
used because they lack the pattern recognition receptor, and since CMPD-1 engages T 
cells circumventing the MHC molecule, there should be no difference in fungal killing in 
B6 T cells and D1KO T cells.  The data was a graphed as a mean of fluorescence of each 
compound per cell type.  Data showed that CMPD-1 did decrease yeast growth more than 
CMPD-2, control and yeast and cells alone.   Although the difference in yeast growth is 
not statistically significant, I think it is still of importance and should be further studied.  
Additionally, patients with polymorphisms in the Dectin-1 receptor or downstream 
signaling pathway are more susceptible to IBD, this showed that CMPD-1 would could 
be used as a therapeutic agent among those with such genetic susceptibility to not only 
IBD, but to fungal infections in general.   
 The data shown here are promising, however, before drawing a conclusion more 
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research is needed.  Therefore, future studies would include: An appropriate way to 
measure fungicidal activity would be the next step.  A more suitable killing assay for this 
infectious model would be determined, perhaps, XTT, or Calcaphor killing assay. This 
would follow determining if compound is toxic to cells. A cell viability assay measuring 
live/ dead T cells would be the way to go.  Eventually, the goal would be to progress to a 
live animal model to test the efficacy of the compound.     
In conclusion, the ‘BiTES’ CMPD-1 shows promising results that with more 
research, this may become a viable treatment for both immunocompromised patients that 
are susceptible to fungal infections, but also to IBD patients experiencing a shift in the 
microbiota creating an aberrant immune response.  
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